ElectroCore, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year Ending December 31, 2021
November 04, 2021 at 04:30 pm EDT
Share
electroCore, Inc. provided revenue guidance for fourth quarter and full year ending December 31, 2021. For the quarter, the company expects revenue to exceed $1.5 million.
For full year, the company expects net revenue to exceed $5.45 million.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Companyâs product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Companyâs TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.
ELECTROCORE, INC. 
